Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 3;10:9027. doi: 10.1038/s41598-020-65915-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

PD-L1 and PD-L2 Expression Levels and Clinical Outcomes in Glioma. (A) Kaplan-Meier disease free survival estimates for GBM patients with high expression of PD-L2 (left) and either high expression of both PD-L1/L2, high expression of either PD-L1/L2, or low expression of both (right)(*p = 0.0072; #, ns = not significant). (B) Kaplan-Meier estimates of OS (left panels) and DFS (right panels) based on high (dark) or low (grey) PD-L2 expression. (C) Kaplan-Meier estimates of OS (left) and DFS (right) in LGG patients with either high expression of both PD-L1/L2, high expression of either PD-L1/L2, or low expression of both (** =p < 0.0001, * = p = 0.009).(D) Multivariate analysis for DFS shows PD-L2 is an independent factor in LGG patients after adjusting by covariates of age, gender and IDH1 mutation (p = 0.0062) (left); Multivariate analysis shows PD-L1/2 both high is independently associated with shorter DFS in LGG patients compared to “both low” (p = 0.0055) or “one high” (p = 0.0452) after adjusting by covariates age, gender and IDH1 mutation (right).